Skip to main content
Woman looking out over city skyline at night

Introducing EBGLYSS
Now approved for patients with moderate-to-severe atopic dermatitis (AD)1

Not an actual patient.

A first-line biologic following topical therapy that can deliver long-lasting relief from the troublesome signs and symptoms of AD with Q4W maintenance dosing.1

What would you like to know?

Double arrows point right icon

START STRONG

Significant skin clearance in IGA* (0,1)† and itch relief on Pruritus NRS‡ seen as early as week 4 and week 2, respectively.1

Hourglass icon

LAST LONG

Efficacy results maintained at 1 year with monthly maintenance dosing.1§

Calendar icon

MAINTAIN MONTHLY

Recommended Q4W maintenance dosing delivers long-lasting efficacy.1§

Globe with magnifying glass icon

WELL-STUDIED SAFETY PROFILE

No boxed warning or lab-monitoring requirements.1
See the safety information for EBGLYSS, including contraindication in patients with prior serious hypersensitivity to lebrikizumab-lbkz or any excipients of EBGLYSS.

  • IGA: A 5-point clinical assessment measure of AD severity in which 0=“clear,” 1=“almost clear,” 2=“mild,” 3=“moderate,” and 4=“severe.”2
  • Responder was defined as a patient with an IGA 0 or 1 (“clear” or “almost clear”) and a reduction of ≥2 points on a 0-4 IGA scale.1
  • Pruritus NRS: a participant-reported, single-item, daily, 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating “No itch” and 10 indicating “Worst itch imaginable.” A change of ≥3 points is considered clinically meaningful.3
  • After a 16-week Q2W induction period or adequate clinical response is achieved, the recommended maintenance dose is 250 mg once every four weeks.1

IGA=Investigator’s Global Assessment; NRS=Numeric Rating Scale; Q2W=every 2 weeks; Q4W=every 4 weeks.

INDICATION

EBGLYSS is indicated for the treatment of adults and pediatric patients 12 years of age and older who weigh at least 40 kg with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids.

SELECT IMPORTANT SAFETY INFORMATION

Contraindication

EBGLYSS is contraindicated in patients with prior serious hypersensitivity to lebrikizumab-lbkz or any excipients of EBGLYSS.

Shining star icon

Want to learn more about EBGLYSS?
Tune in and hear from an AD expertCaretRight

Experience EBGLYSS video series

Stream the series on Lilly Play

References:

  1. EBGLYSS (lebrikizumab-lbkz). Prescribing Information. Lilly USA, LLC.
  2. Data on File. Lilly USA, LLC. DOF-LK-US-0007.
  3. Yosipovitch G, Rams A, Baldasaro J, et al. Content validity and assessment of the psychometric properties and score interpretation of a Pruritus Numeric Rating Scale in atopic dermatitis. Poster presented at: Annual Revolutionizing Atopic Dermatitis (RAD) Conference; December 11-13, 2021; Chicago, IL.

IMPORTANT SAFETY INFORMATION

Contraindication: EBGLYSS is contraindicated in patients with prior serious hypersensitivity to lebrikizumab-lbkz or any excipients of EBGLYSS.

Warnings and Precautions

Hypersensitivity
Hypersensitivity reactions, including angioedema and urticaria, have been reported with use of EBGLYSS. If a serious hypersensitivity reaction occurs, discontinue EBGLYSS and institute appropriate therapy.

Conjunctivitis and Keratitis
Conjunctivitis and keratitis adverse reactions have been reported in clinical trials. Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received EBGLYSS compared to those who received placebo. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered during the treatment period. Advise patients to report new onset or worsening eye symptoms to their healthcare provider.

Parasitic (Helminth) Infections
Patients with known helminth infections were excluded from participation in clinical studies. It is unknown if EBGLYSS will influence the immune response against helminth infections by inhibiting IL-13 signaling. Treat patients with pre-existing helminth infections before initiating treatment with EBGLYSS. If patients become infected while receiving EBGLYSS and do not respond to antihelminth treatment, discontinue treatment with EBGLYSS until the infection resolves.

Vaccinations
EBGLYSS may alter a patient’s immunity and increase the risk of infection following administration of live vaccines. Prior to therapy with EBGLYSS, complete all age-appropriate vaccinations according to current immunization guidelines. Avoid use of live vaccines immediately prior to or during treatment with EBGLYSS. No data are available on the response to live vaccines.

Adverse Reactions

The most common (≥1%) adverse reactions are conjunctivitis, injection site reactions, and herpes zoster.

EBGLYSS is available as a 250mg/2mL subcutaneous injection prefilled pen or prefilled syringe.

Please click to access Prescribing Information and Patient Information.
Please see Instructions for Use included with the device.

LK HCP ISI AD APP

INDICATION

EBGLYSS is indicated for the treatment of adults and pediatric patients 12 years of age and older who weigh at least 40 kg with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids.